Stock Movers: Eli Lilly Drug Study, AbbVie Profit Boost, Warner Bros. Layoffs

Eli Lilly's Mounjaro Study Results

• 💡 Eli Lilly's blockbuster diabetes drug, Mounjaro, did not meet expectations in a head-to-head study against its older medicine, Trulicity, for preventing heart attacks and strokes.
• 🎯 The study aimed to prove non-inferiority, meaning Mounjaro would be an acceptable alternative for reducing cardiovascular risk compared to Trulicity.
• 📉 The results were disappointing for investors, as Mounjaro was not found to be meaningfully better than Trulicity in this trial involving over 13,000 participants.

AbbVie's Strong Financial Performance

• 📈 AbbVie (ABBV) raised its full-year profit forecast, driven by strong sales from its newer immunology drugs.
• 📊 The company exceeded Wall Street estimates, reporting second-quarter sales of $15.42 billion and adjusted earnings per share of $2.97, a 12% increase.
• 🔑 AbbVie has successfully navigated patent expirations on its former blockbuster drug, Humira, and has avoided challenges faced by some industry peers.

Warner Bros. Discovery Layoffs

• ✂️ Warner Bros. Discovery is implementing layoffs affecting approximately 10% of its workforce across marketing, production strategy, operations, and theater ventures.
• 🏢 This move comes as the parent company prepares to split into two new publicly traded entities: Warner Bros. (film, TV studios, streaming) and Discovery Global (TV networks, Discovery Plus, other assets).
• 📰 The layoffs impact various divisions within the studio's motion picture group.